Video:
FDA Class I Recall: Olympus High-Flow Laparoscopic Insufflation Units Pulled Over Overpressure Risk

The U.S. surgical community is responding to a Class I medical device recall involving certain high-flow laparoscopic insufflation units manufactured by Olympus Corporation. The recall, published by the U.S. Food and Drug Administration, affects specific models of the UHI, UHI-2, and UHI-3 High Flow Insufflation Units, devices widely used to establish and maintain pneumoperitoneum during minimally invasive procedures.

According to the FDA safety communication, the affected units may experience a software algorithm malfunction that can lead to overpressure events, potentially exposing patients to elevated intra-abdominal pressure during laparoscopic surgery. The FDA classified the action as a Class I recall, the agency’s most serious recall category, indicating that use of the product could cause serious adverse health consequences or death.

Olympus initiated a recall for certain High Flow Insufflation Units (UHI series) after identifying a potential issue with the device’s internal software control algorithm. The malfunction may allow the unit to deliver higher-than-intended insufflation pressure, creating a risk of:

• Excessive intra-abdominal pressure

• Cardiovascular or respiratory compromise

• Organ or tissue injury

Olympus notified customers to stop using the affected devices immediately and transition to alternative equipment. The FDA’s recall notice instructs facilities to follow Olympus’ field corrective action guidance and to return or replace affected units as directed.

Insufflation systems are core equipment in laparoscopic surgery, used across:

• General surgery

• Gynecology

• Urology

• Bariatrics

• Thoracic procedures (select minimally invasive cases)

Because insufflators regulate gas pressure and flow to create surgical working space, pressure control integrity is essential for patient safety.

1. Immediate OR Equipment Impact

High-flow insufflators are standard equipment in minimally invasive operating rooms. A recall requiring facilities to remove units from service can have operational consequences such as:

• Delayed laparoscopic cases if backup units are unavailable

• Increased demand for rental or loaner equipment

• Temporary device substitution across service lines

Facilities with limited redundancy in their laparoscopic towers or energy systems may experience workflow disruptions.

2. Sterile Processing & Biomed Coordination

Although insufflators are capital devices rather than disposables, recalls of this nature trigger:

• Biomedical engineering inspections and quarantine procedures

• Equipment tracking audits

• Reassignment of laparoscopic towers

• Coordination between OR, SPD, and clinical engineering

Supply chain leaders must ensure inventory visibility and equipment tracking accuracy to prevent recalled units from remaining in circulation.

3. Vendor Diversification & Contract Implications

Hospitals relying heavily on Olympus laparoscopic platforms may need to:

• Temporarily integrate alternative insufflation units

• Assess cross-compatibility with existing trocars and tubing

• Review preventive maintenance and software validation protocols

This event highlights the importance of maintaining multi-vendor readiness for critical surgical platforms.

• Operating room teams performing laparoscopic procedures

• Surgical service line directors overseeing MIS volumes

• Biomedical engineering departments responsible for device validation

• Supply chain and capital equipment managers coordinating replacements

• Ambulatory surgery centers (ASCs) with limited device redundancy

Minimally invasive procedures represent a significant percentage of elective and inpatient surgical volume in the U.S. Any disruption in insufflation capacity can directly affect scheduling stability.

“Pressure regulation is foundational to laparoscopic safety. Any malfunction that alters intra-abdominal pressure control requires immediate action to prevent patient harm and maintain procedural integrity.”

— Statement attributed to FDA recall classification guidance

The FDA’s Class I designation underscores that even software-driven irregularities in surgical capital equipment warrant rapid mitigation.

Immediate Actions

• Confirm whether any UHI, UHI-2, or UHI-3 units are in active service.

• Remove affected units per manufacturer guidance.

• Coordinate with Olympus for corrective actions or replacement.

Operational Safeguards

• Validate backup insufflation capacity before resuming full laparoscopic scheduling.

• Conduct OR staff briefings to ensure awareness of affected models.

• Document recall compliance for regulatory readiness.

Longer-Term Supply Chain Planning

• Review equipment redundancy strategies for critical laparoscopic infrastructure.

• Ensure device software validation is part of capital equipment lifecycle management.

• Integrate recall monitoring into procurement dashboards for real-time risk awareness.